The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis

Figure 1. The base-case patient has chronic arthritis, is at average risk for ulcer complications, and is not taking concurrent aspirin. The clinician may either treat with naproxen, 500 mg twice daily, or with a coxib, once daily. The extended tree ( ) is shared by the coxib arm, with the exception of switching to coxibs if ulcer complications develop. See text for details about individual strategies and for assumptions about downstream costs and effects (not represented in the figure). EGD = esophagogastroduodenoscopy; GI = gastrointestinal; NUD = nonulcer dyspepsia; PPI = proton-pump inhibitor.
Figure 1. The base-case patient has chronic arthritis, is at average risk for ulcer complications, and is not taking concurrent aspirin. The clinician may either treat with naproxen, 500 mg twice daily, or with a coxib, once daily. The extended tree ( ) is shared by the coxib arm, with the exception of switching to coxibs if ulcer complications develop. See text for details about individual strategies and for assumptions about downstream costs and effects (not represented in the figure). EGD = esophagogastroduodenoscopy; GI = gastrointestinal; NUD = nonulcer dyspepsia; PPI = proton-pump inhibitor. Truncated decision model.A

This Article

  1. Ann Intern Med May 20, 2003 vol. 138 no. 10 795-806
  1. AbstractFREE
  2. Figures
  3. Full Text
  4. Full Text (PDF)

Current Issue

  1. December 1, 2009, 151 (11)
  1. Alert me to current issues